BUZZ-Hoth Therapeutics rises as early obesity‑drug data in mice shows promise
Reuters
Feb 10
BUZZ-<a href="https://laohu8.com/S/HOTH">Hoth Therapeutics</a> rises as early obesity‑drug data in mice shows promise
** Shares of Hoth TherapeuticsHOTH.O rise 3.9% to $0.89 premarket
** Co says its experimental obesity drug HT‑VA GDNF helped mice gain less weight and stabilize weight compared with semaglutide
** Co says the drug also improved blood sugar and reduced liver weight, which could help fatty liver disease — a liver condition linked to obesity
** The 12‑week study was conducted in female mice placed on a high‑fat diet, in collaboration with the U.S. Veterans Administration
** Co says it plans to start human trials in 2027 and is also developing treatments for cancer‑related skin problems and Alzheimer’s
** Shares up ~32% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.